114 related articles for article (PubMed ID: 38892467)
1. Cilostazol Attenuates Hepatic Steatosis and Intestinal Disorders in Nonalcoholic Fatty Liver Disease.
Min T; Qiu S; Bai Y; Cao H; Guo J; Su Z
Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892467
[TBL] [Abstract][Full Text] [Related]
2. Cilostazol Improves HFD-Induced Hepatic Steatosis by Upregulating Hepatic STAMP2 Expression through AMPK.
Oh YJ; Kim HY; Lee MH; Suh SH; Choi Y; Nam TG; Kwon WY; Lee SY; Yoo YH
Mol Pharmacol; 2018 Dec; 94(6):1401-1411. PubMed ID: 30366981
[TBL] [Abstract][Full Text] [Related]
3. Ling-Gui-Zhu-Gan decoction ameliorates nonalcoholic fatty liver disease via modulating the gut microbiota.
Chen L-p; Zhang L-f; Liu S; Hua H; Zhang L; Liu B-c; Wang R-r
Microbiol Spectr; 2024 Jun; 12(6):e0197923. PubMed ID: 38647315
[TBL] [Abstract][Full Text] [Related]
4. Xiaozhi formula attenuates non-alcoholic fatty liver disease by regulating lipid metabolism via activation of AMPK and PPAR pathways.
You L; Wang T; Li W; Zhang J; Zheng C; Zheng Y; Li S; Shang Z; Lin J; Wang F; Qian Y; Zhou Z; Kong X; Gao Y; Sun X
J Ethnopharmacol; 2024 Jul; 329():118165. PubMed ID: 38588984
[TBL] [Abstract][Full Text] [Related]
5. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
[TBL] [Abstract][Full Text] [Related]
6. Kangtaizhi Granule Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats and HepG2 Cells via AMPK/mTOR Signaling Pathway.
Zhang J; Du H; Shen M; Zhao Z; Ye X
J Immunol Res; 2020; 2020():3413186. PubMed ID: 32884949
[TBL] [Abstract][Full Text] [Related]
7. Si Miao Formula attenuates non-alcoholic fatty liver disease by modulating hepatic lipid metabolism and gut microbiota.
Han R; Qiu H; Zhong J; Zheng N; Li B; Hong Y; Ma J; Wu G; Chen L; Sheng L; Li H
Phytomedicine; 2021 May; 85():153544. PubMed ID: 33773192
[TBL] [Abstract][Full Text] [Related]
8. Targeting the gut microbiota with resveratrol: a demonstration of novel evidence for the management of hepatic steatosis.
Wang P; Wang J; Li D; Ke W; Chen F; Hu X
J Nutr Biochem; 2020 Jul; 81():108363. PubMed ID: 32388250
[TBL] [Abstract][Full Text] [Related]
9. Psoralea corylifolia L. extract ameliorates nonalcoholic fatty liver disease in free-fatty-acid-incubated HEPG2 cells and in high-fat diet-fed mice.
Hong Y; Choi SI; Hong E; Kim GH
J Food Sci; 2020 Jul; 85(7):2216-2226. PubMed ID: 32579753
[TBL] [Abstract][Full Text] [Related]
10. 1,2,3,4,6 penta-O-galloyl-β-D-glucose ameliorates high-fat diet-induced nonalcoholic fatty liver disease and maintains the expression of genes involved in lipid homeostasis in mice.
Kant R; Lu CK; Nguyen HM; Hsiao HH; Chen CJ; Hsiao HP; Lin KJ; Fang CC; Yen CH
Biomed Pharmacother; 2020 Sep; 129():110348. PubMed ID: 32554245
[TBL] [Abstract][Full Text] [Related]
11. Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway.
Zhu X; Bian H; Wang L; Sun X; Xu X; Yan H; Xia M; Chang X; Lu Y; Li Y; Xia P; Li X; Gao X
Free Radic Biol Med; 2019 Sep; 141():192-204. PubMed ID: 31226399
[TBL] [Abstract][Full Text] [Related]
12. Tetrahydropalmatine ameliorates hepatic steatosis in nonalcoholic fatty liver disease by switching lipid metabolism via AMPK-SREBP-1c-Sirt1 signaling axis.
Yin X; Liu Z; Wang J
Phytomedicine; 2023 Oct; 119():155005. PubMed ID: 37562090
[TBL] [Abstract][Full Text] [Related]
13. Lonicerae flos polysaccharides improve nonalcoholic fatty liver disease by activating the adenosine 5'-monophosphate-activated protein kinase pathway and reshaping gut microbiota.
Han C; Li Z; Liu R; Zhao Z; Wang Y; Zuo X; Zhang Y; Geng Z; Huang H; Pan X; Li W
J Sci Food Agric; 2023 Dec; 103(15):7721-7738. PubMed ID: 37439182
[TBL] [Abstract][Full Text] [Related]
14. Anti-hepatic steatosis activity of Sicyos angulatus extract in high-fat diet-fed mice and chemical profiling study using UHPLC-qTOF-MS/MS spectrometry.
An JP; Choi JH; Huh J; Lee HJ; Han S; Noh JR; Kim YH; Lee CH; Oh WK
Phytomedicine; 2019 Oct; 63():152999. PubMed ID: 31280138
[TBL] [Abstract][Full Text] [Related]
15. Chitosan Oligosaccharide Attenuates Nonalcoholic Fatty Liver Disease Induced by High Fat Diet through Reducing Lipid Accumulation, Inflammation and Oxidative Stress in C57BL/6 Mice.
Tao W; Sun W; Liu L; Wang G; Xiao Z; Pei X; Wang M
Mar Drugs; 2019 Nov; 17(11):. PubMed ID: 31744059
[TBL] [Abstract][Full Text] [Related]
16. Desulfovibrio vulgaris, a potent acetic acid-producing bacterium, attenuates nonalcoholic fatty liver disease in mice.
Hong Y; Sheng L; Zhong J; Tao X; Zhu W; Ma J; Yan J; Zhao A; Zheng X; Wu G; Li B; Han B; Ding K; Zheng N; Jia W; Li H
Gut Microbes; 2021; 13(1):1-20. PubMed ID: 34125646
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Mechanism of Polymerized Anthocyanin from Grape-Skin Extract on High-Fat-Diet-Induced Nonalcoholic Fatty Liver Disease.
Fan M; Choi YJ; Tang Y; Bae SM; Yang HP; Kim EK
Nutrients; 2019 Oct; 11(11):. PubMed ID: 31717842
[TBL] [Abstract][Full Text] [Related]
18. Chicoric Acid Ameliorates Nonalcoholic Fatty Liver Disease via the AMPK/Nrf2/NF
Ding X; Jian T; Li J; Lv H; Tong B; Li J; Meng X; Ren B; Chen J
Oxid Med Cell Longev; 2020; 2020():9734560. PubMed ID: 33204402
[TBL] [Abstract][Full Text] [Related]
19. Sex-specific maternal calcium requirements for the prevention of nonalcoholic fatty liver disease by altering the intestinal microbiota and lipid metabolism in the high-fat-diet-fed offspring mice.
Li P; Yan K; Chang X; Chen X; Wang R; Fan X; Tang T; Zhan D; Qi K
Gut Microbes; 2020 Nov; 11(6):1590-1607. PubMed ID: 32576050
[TBL] [Abstract][Full Text] [Related]
20. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.
Jiang C; Xie C; Li F; Zhang L; Nichols RG; Krausz KW; Cai J; Qi Y; Fang ZZ; Takahashi S; Tanaka N; Desai D; Amin SG; Albert I; Patterson AD; Gonzalez FJ
J Clin Invest; 2015 Jan; 125(1):386-402. PubMed ID: 25500885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
